A candidate subunit vaccine against Nipah virus has demonstrated good safety, tolerability and ability to induce an immune response in humans in a phase 1 study. The vaccine, referred to as PHV02, is being developed with CEPI support and has successfully passed initial clinical trials, confirming its potential to rapidly induce protection after just one dose. Phase II clinical trials are currently underway and are planned to enrol approximately 500 adults and 75 children in areas with high virus prevalence, such as Bangladesh. Nipah virus is highly lethal, with a mortality rate of up to 75%, and there are as yet no approved treatments or vaccines against it. Vaccine development is therefore urgent given the recurrent epidemics and the high risk of the virus spreading. In addition to the PHV02 vaccine, other approaches are being explored, such as adenovirus vector-based vaccines, which have demonstrated rapid and complete protection against infection in experimental models. The World Health Organization rates the risk of Nipah virus at the national level as moderate, but given the high mortality and lack of treatment, continued development of effective means of protection is needed[1][3][4][5].